ARCA biopharma, Inc. (ABIO)
收市後：
| 前收市價 | 3.2500 |
| 開市 | 3.2400 |
| 買盤 | 3.2000 x 200 |
| 賣出價 | 3.3000 x 200 |
| 今日波幅 | 3.1700 - 3.3600 |
| 52 週波幅 | 1.5600 - 4.4900 |
| 成交量 | |
| 平均成交量 | 1,472,164 |
| 市值 | 47.293M |
| Beta 值 (5 年，每月) | 0.88 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.4200 |
| 業績公佈日 | 2024年7月19日 - 2024年7月23日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
InvestorPlace3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally
Yesterday, the forgotten meme stocks of 2021 started picking up serious momentum. But unlike 2021, it didn’t take much to see the reason behind GameStop’s (NYSE:GME) sudden surge. Keith Gill, the Massachusetts financial advisor credited with launching the GME short squeeze of 2021, unexpectedly returned to social media, posting a single, cryptic image on his X account, where he goes by the alias Roaring Kitty. The image showed a hand-drawn man playing video games with no caption or further conte
BenzingaSmall-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details
ARCA Biopharma Inc (NASDAQ:ABIO) and Oruka Therapeutics have entered into a definitive agreement to combine the companies in an all-stock transaction. Oruka Therapeutics is a privately held biotechnology company developing novel biologics for chronic skin diseases, including plaque psoriasis. The resulting entity will focus on advancing Oruka’s pipeline, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to o
